Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM@ASCO
ALT Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.
The @doximity Residency Navigator ranked 24 @UMich residency programs among the top 25 in the nation. A big shoutout to our outstanding residency programs and the teams behind them! michmed.org/rwVQq
ALT Promotional image featuring an aerial view of University of Michigan Medical School campus, highlighted for having over 20 top-ranked residency programs, according to Doximity.
Excited about our new work on lymph node mapping ultrasound for thyroid cancer in @JSurgRes!
More predictive ultrasound ➡️ higher yield FNA ➡️ lower costs and fewer unnecessary operations
pubmed.ncbi.nlm.nih.gov/3878…@BeninatoToni@amlaird
Today is National #DoctorsDay, a chance to recognize the thousands of physicians, residents and fellows who help Michigan Medicine advance health every day.
THANK YOU, doctors, for all you do at Michigan Medicine. Hail! #NationalDoctorsDay
📷: Illustration by Justine Ross.